We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Sarah Whelan, PhD

Sarah Whelan, PhD profile page

Science Writer

 at Technology Networks


Sarah joined Technology Networks in 2022 after completing a PhD in cancer biology, where her research focused on the development of colon cancers. In her role as science writer and editor, Sarah covers scientific news and a range of other content types, leading the site's coverage of drug discovery, biopharma and cancer research content.


Education


University of Kent  

University of Leicester  


Areas of Expertise



Got a Question for Sarah Whelan, PhD?


Get in touch using the contact form linked here and we’ll get back to you shortly.



Published Content
Total: 305
Computer-generated image of cells.
News

Risk of Secondary Cancer Investigated After CAR T-Cell Therapy

A study by University of Pennsylvania researchers shows that secondary cancer development is rare after CAR T-cell therapy and that many patients have achieved long-lasting remission.
A blue and red pill split open showing a drug molecular structure.
News

Pulling “Ineffective” Decongestant From Shelves Could Disrupt Supply Chain

Despite an FDA panel suggesting oral phenylephrine is ineffective, it remains popular among consumers and pulling it from the shelves could create supply chain disruptions, according to a new study.
A person wearing gloves drawing up a vaccine into a syringe.
News

Single-Dose Dengue Vaccine Provides Nearly 80% Protection

Results from a Phase 3 clinical trial show that the vaccine is safe and effective for those aged 2–59 regardless of whether they have previously been infected with dengue.
A three-dimensional structure of a PNMA2 complex.
News

Virus-Like Brain Protein May Explain Cancer-Induced Memory Loss

Some tumors can produce virus-like proteins that kick-start out-of-control immune reactions, according to a new study from University of Utah researchers. These rare cancer complications can lead to memory loss and cognitive deficits caused by the immune system attacking the brain.
An illustration of editing of a DNA double helix.
News

Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness

Five out of six children with a type of hereditary hearing loss have shown improvement in their hearing and speech recognition after treatment with an experimental gene therapy. This is the first gene therapy trial for children with this type of hearing loss.
A person receiving a vaccine shot in their arm.
News

No Cervical Cancer Cases Following HPV Vaccination in Scotland

No cervical cancer cases have been observed in women who received the human papillomavirus (HPV) vaccine at age 12 or 13 in Scotland since the program began in 2008, according to a new study.
A white plate filled with white pills.
News

Experimental Insulin Pill Could Reduce Need for Injections

Researchers have developed an oral form of insulin that lowers glucose levels in animal models. The oral insulin, encased in a nano-carrier that delivers insulin to the liver, is expected to begin human trials in 2025.
A person holding chicken eggs.
News

Could Chicken Eggs Be a Low-Cost Option for Cancer Studies?

Researchers from King’s College London (KCL) suggest that fertilized chicken eggs could provide a low-cost option for cancer imaging studies, potentially helping to resolve some ethical and economic issues.
Computer-generated image of some cells.
News

Energy-Starved Breast Cancer Cells Scavenge From Their Surroundings

Breast cancer cells can consume their surroundings to overcome starvation and continue cell growth, according to a new study, which describes a previously unknown method of cancer cell survival.
A collection of many different pills.
News

2023 Saw Second-Highest Number of Drug Approvals in 30 Years

The US FDA approved 55 novel drugs in 2023 – the second-highest figure in the last 30 years. This is almost a 50% increase compared to 2022, which saw 37 new approvals.
Advertisement